ArticlePloS one2025
Dual efficacy-toxicity of Chelidonii Herba in chronic obstructive pulmonary disease: Integrated network pharmacology, immune profiling and molecular docking.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the pharmacodynamic material basis, multi-target mechanisms of Chelidonii Herba in treating chronic obstructive pulmonary disease (COPD), and its hepatotoxicity pathways using network pharmacology, network toxicology, and molecular docking.
methodsActive components and targets of Chelidonii Herba were screened via Traditional Chinese Medicine Systems Pharmacology (TCMSP), SwissTargetPrediction (STP), and PharmMapper databases. COPD and hepatotoxicity targets were obtained from GeneCards and OMIM. Venn diagrams identified shared targets. Protein-protein interaction (PPI) networks were constructed using STRING, with core targets filtered via CytoNCA. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed in Metascape. Molecular docking was validated by AutoDock Vina, and immune infiltration was analyzed using the GSE55962 dataset.
resultsTwenty active components and 108 potential targets of Chelidonii Herba were identified. Eighty shared targets intersected with COPD, and 96 with hepatotoxicity. Seven core targets for COPD treatment (CASP3, PPARG, PTGS2, CDK2, ALB, HSP90AA1, ESR1) and hepatotoxicity (PPARG, ESR1, CASP3, PTGS2, ESR2, CALM3, ALB) were determined. KEGG enrichment revealed COPD mechanisms involving PI3K-Akt, VEGF, and cGMP-PKG pathways, while hepatotoxicity implicated VEGF, PI3K-Akt, and estrogen signaling. Core components (e.g., dihydrochelerythrine, oxysanguinarine) exhibited strong binding to targets (binding energy ≤ -5.0 kcal/mol, partial ≤ -7.0 kcal/mol). Immune infiltration analysis linked core targets to macrophages M2 and γδ T cells.
conclusionChelidonii Herba treats COPD primarily through alkaloids modulating shared targets (CASP3, PPARG, PTGS2) via PI3K-Akt pathways, while concurrently inducing hepatotoxicity through VEGF and estrogen signaling. This dual efficacy-toxicity profile necessitates cautious clinical application and experimental validation to define safe therapeutic windows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.